natgillin/translations-raw huggingface dataset:
TURQUOISE-II was a randomised, global multicentre, open-label trial conducted exclusively in 380 genotype 1-infected subjects with compensated cirrhosis (Child-Pugh A) who were either treatment- naïve or did not achieve SVR with prior treatment with pegIFN/RBV.
SAPPHIRE-II bilo je randomizirano, globalno, multicentrično, dvostruko slijepo, placebom kontrolirano ispitivanje provedeno u 394 ispitanika s kroničnom infekcijom virusom hepatitisa C genotipa 1 bez ciroze koji nisu postigli SVR uz prethodno liječenje kombinacijom pegIFN/RBV.
TURQUOISE-II – treatment-naïve or pegIFN + RBV-experienced with compensated cirrhosis
TURQUOISE-II – ispitanici s kompenziranom cirozom, prethodno neliječeni ili prethodno liječeni pegIFN i RBV
TURQUOISE-II: relapse rates by baseline laboratory values after 12 and 24 weeks of treatment in subjects with genotype 1a infection and compensated cirrhosis
TURQUOISE-II: Stope relapsa u odnosu na početne laboratorijske vrijednosti u ispitanika s infekcijom genotipom 1a i kompenziranom cirozom nakon 12 i 24 tjedna liječenja
TURQUOISE-III: Clinical Trial of GT1b-Infected Subjects with Cirrhosis without RBV
TURQUOISE-III: Kliničko ispitivanje provedeno u ispitanika s infekcijom genotipom 1b i cirozom bez ribavirina
TURQUOISE-III: treatment-naïve or pegIFN + RBV-experienced with compensated cirrhosis
TURQUOISE-III: ispitanici s kompenziranom cirozom, prethodno neliječeni ili prethodno liječeni pegIFN i RBV
TURQUOISE-II– genotype 1, treatment-naïve or peginterferon+ribavirin-experienced subjects with compensated cirrhosis
SAPPHIRE-II –ispitanici s infekcijom genotipom 1 prethodno liječeni kombinacijom peginterferon+ribavirin
Tutti frutti flavour (contains sorbitol) Carmellose sodium Hydroxyethylcellulose
Tutti frutti okus (sadrži sorbitol) Karmelozanatrij Hidroksietilceluloza
TVC-naïve(1)
TVC-neizloženi (1)
TVR - target vessel revascularization
TVR – revaskularizacija ciljne k. žile (engl. target vessel revascularization)
TW 48.
mjerljiva
Twelve (0.37%) enrolled patients experienced thrombus in the arterial sheath, of these 7 were reported during angiography and 5 were reported during PCI.
U dvanaest je bolesnika (0,37%) došlo do tromboze u arterijskoj uvodnici, od čega 7 tijekom angiografije i 5 tijekom PCI.
Twelve and twenty-four months after vaccination, the neutralising antibody titres were as follows:
12 i 24 mjeseca nakon cijepljenja, titri neutralizirajućih protutijela bili su sljedeći:
Twelve and twenty-four months after vaccination, the neutralising antibody titres were as follows:
Dvanaest i 24 mjeseca nakon cijepljenja, titri neutralizirajućih antitijela bili su sljedeći:
Twelve double-blind, placebo controlled, 6/8-week, fixed-dose studies have been conducted to investigate the short-term efficacy of vortioxetine in MDD in adults (including the elderly).
Provedeno je dvanaest dvostruko slijepih placebom kontroliranih, 6/8 tjednih ispitivanja fiksnih doza kako bi se istražila kratkoročna djelotvornost vortioksetina kod MDD-a u odraslih (uključujući starije osobe).
Twelve months after the first dose, the seroprotection rate was as follows:
Dvanaest mjeseci nakon prve doze zabilježene su slijedeće vrijednosti stopa seroprotekcije:
Twelve months seizure freedom
Dvanaest mjeseci bez napadaja
Twelve months seizure freedom
Šest mjeseci bez napadaja
Twelve of the fifteen patients died within 30 days of the last dose of necitumumab and had comorbid conditions including history of coronary artery disease (n=3), hypomagnesemia (n=4), chronic obstructive pulmonary disease (n=7), and hypertension (n=5).
Dvanaest od tih 15 bolesnika umrlo je unutar 30 dana nakon posljednje doze necitumumaba, a imalo je komorbiditetna stanja, uključujući bolest koronarnih arterija (n=3), hipomagnezijemiju (n=4), kroničnu opstruktivnu plućnu bolest (n=7) i hipertenziju (n=5) u anamnezi.
Twenty cats naturally infested with lungworm were treated with Broadline.
Dvadeset mačaka prirodno infestiranih plućnim crvom liječeno je VMP-om Broadline.
Twenty four patients were treated for 28 days with 150 mg nintedanib twice daily (13 patients received nintedanib on top of chronic treatment with standard doses of pirfenidone; 11 patients received nintedanib alone).
Dvadeset četiri bolesnika liječeno je tijekom 28 dana s 150 mg nintedaniba dvaput dnevno (13 bolesnika je primalo nintedanib uz kronično liječenje standardnim dozama pirfenidona; 11 bolesnika je primalo samo nintedanib).
Twenty four percent of children (11/46) treated for 24 weeks and 40 % of children (19/48) treated for 48 weeks had a > 15 percentile height for age decrease from pre treatment to the end of 5 year long term follow up compared to pre treatment baseline percentiles.
U 24% djece (11/46) liječene 24 tjedna i 40% djece (19/48) liječene 48 tjedana zabilježen je pad za > 15 percentila na percentilnoj krivulji visine za dob od razdoblja prije početka liječenja do kraja 5-godišnjeg dugotrajnog praćenja u usporedbi s percentilima prije početka liječenja.
Twenty mild to moderately immunocompromised children and adolescents 5 through 17 years of age (receiving chemotherapy and/or radiation therapy or who had recently received chemotherapy) were randomized 1:1 to trivalent Fluenz or placebo.
Dvadesetero blago do umjereno imunokompromitirane djece i adolescenata u dobi od 5 do 17 godina starosti (koji primaju kemoterapiju i/ili radioterapiju ili koji su nedavno primili kemoterapiju) randomizirano je 1:1 prema primanju trovalentnog cjepiva Fluenz ili placeba.
Twenty of the 24 patients who required dialysis at baseline were able to discontinue dialysis during Soliris treatment.
Od 24 bolesnika kojima je bila potrebna dijaliza na početku ispitivanja, njih 20 moglo je prekinuti dijalizu za vrijeme liječenja lijekom Soliris.
Twenty out of 23 children and adolescents (87%) had >1 log10 c/mL decrease from Baseline in HIV-1 RNA or HIV-1 RNA <400 c/mL at Week 24.
U 20 od 23 djece i adolescenata (87%) razina HIV-1 RNK nakon 24 tjedna smanjila se za >1 log10 kopija/ml u odnosu na početnu vrijednost ili je iznosila < 400 kopija/ml.
Twenty patients (50%) experienced leukocytosis; however, in all these patients, the WBC count was declining or had normalized by the time of bone marrow remission and cytotoxic chemotherapy or leukopheresis was not required.
Dvadeset bolesnika (50%) imalo je leukocitozu; međutim, kod svih tih bolesnika broj leukocita bio je u padu ili se normalizirao do vremena remisije koštane srži pa citotoksična terapija ili leukofereza nije bila potrebna.
Twenty patients used median doses of more than 45 IU/kg.
Dvadeset bolesnika koristilo je dozu medijana većeg od 45 IU/kg.
Twenty seven (7%) out of 389 patients enrolled in study 301 and 14 (4.1%) out of 342 enrolled in study 302 were not randomised due to a positive mannitol tolerance test (MTT) defined as either 1) a fall in FEV1 >20% from baseline at midpoint (step 4) or 2) fall from baseline > 20 % at end of test that did not recover to < 20% within 15 minutes or 3) who had a fall in FEV1 > 50% from baseline at end of test (step 6) or 4) who had a fall in Sp02 to < 89% during the procedure.
Dvadeset sedam (7%) od 389 pacijenata uključenih u ispitivanje 301 i 14 (4,1%) pacijenata od 342 pacijenta uključena u ispitivanje 302 nisu razvrstani zbog pozitivnog testa tolerancije na manitol (MTT), koja se definira kao 1) smanjenje vrijednosti FEV1 za > 20% u odnosu na početnu vrijednost u središnjoj točki (4. korak); ili 2) smanjenje početne vrijednosti za > 20 % u odnosu na početnu vrijednost na kraju testa te nemogućnost vraćanja na < 20% unutar 15 minuta; ili 3) smanjenje vrijednosti FEV1 za > 50% u odnosu na srednju vrijednost na kraju testa (6. korak); ili 4) smanjenje vrijednosti SpO2 na < 89% tijekom postupka.
Twenty seven (7%) out of 389 patients enrolled in study 301 and 14 (4.1%) out of 342 enrolled in study 302 were not randomised due to a positive mannitol tolerance test (MTT).
Dvadeset i sedam (7%) pacijenata od 389 uključenih u ispitivanje 301 i 14 (4,1%) pacijenata od 342 uključena u ispitivanje 302 nisu razvrstani zbog pozitivnog testa tolerancije na manitol (MTT, engl. mannitol tolerance test).
Twenty- four patients had neutropaenia.
24 bolesnika imalo je neutropeniju.
Twenty- three patients out of 115 experienced a vascular disorder considered to be related to clofarabine, the most frequently reported being flushing (13 events; not serious) and hypotension (5 events; all of which were considered to be serious; see section 4.4).
U 23 od 115 bolesnika javili su se krvožilni poremećaji koji se smatraju povezanima s klofarabinom, a među njima su najčešće prijavljivani bili navale crvenila (13 događaja; nisu bili ozbiljni) i hipotenzija (5 događaja; svi su se smatrali ozbiljnima; vidjeti dio 4.4).
Twenty-eight (5%) of the 511 patients experienced a fatal infection.
Dvadeset i osam (5%) od 511 bolesnika imalo je infekciju sa smrtnim ishodom.
Twenty-eight of the 231 patients (12.1%) on vandetanib and 3 of the 99 (3.0%) on placebo discontinued treatment because of an adverse event.
Dvadeset i osam od 231 bolesnika (12,1%) liječenih vandetanibom i 3 od 99 (3,0%) bolesnika koji su primali placebo prekinulo je liječenje zbog štetnog događaja.
Twenty-eight patients with mild to moderate type 1 Gaucher disease were enrolled in this 12-month non-comparative study, and 22 patients completed the study.
Dvadesetosam bolesnika s blagom ili umjerenom Gaucherovom bilesti tipa 1 uključeni su u ovo 12- mjesečno nekomparativno ispitivanje, a 22 bolesnika su završila ispitivanje.
Twenty-one (18.3%) events were considered to be related to clofarabine of which catheter related infection (1 event), sepsis (2 events) and septic shock (2 events; 1 patient died (see above)) were considered to be serious.
S klofarabinom se smatrao povezanim 21 (18,3%) događaj, od kojih su se ozbiljnima smatrali infekcija povezana s kateterom (1 događaj), sepsa (2 događaja) i septički šok (2 događaja; 1 bolesnik je preminuo (vidjeti gore)).
Twenty-one days after the second dose, a 4-fold increase in serum neutralising antibody against A/Indonesia/5/2005 was achieved in 94.4% of subjects aged 18-60 years and in 80.4% of subjects over 60 years of age.
Dvadeset i jedan dan nakon druge doze, u osoba od 18 do 60 godina postignut je četverostruki porast neutralizirajućih protutijela protiv A/Indonesia/5/2005 u serumu 94,4% ispitanika, a u osoba starijih od 60 godina u 80,4% ispitanika.
Twenty-one days after the second injection, 86% of the people receiving the vaccine with 7.5 micrograms haemagglutinin had levels of antibodies that would protect them against H5N1.
Dvadeset i jedan dan nakon druge injekcije 86% osoba koje je primilo cjepivo sa 7,5 mikrograma hemaglutinina imalo je razine protutijela koje će ih štititi od H5N1.
Twenty-one patients treated with Revestive (48.8%) versus 9 on placebo (20.9%) achieved at least a one day reduction in parenteral nutrition administration (p=0.008).
Dvadeset jedan bolesnik liječen lijekom Revestive (48,8%) naspram 9 koji su primali placebo (20,9%) smanjio je primjenu parenteralne prehrane (p=0,008) barem za jedan dan.
Twenty-seven (27, 75%) had undergone a nephrectomy.
U njih 27 (27, 75%) je učinjena nefrektomija.
Twenty-six patients continued to receive bosentan in the 24-week open-label extension phase (AC-052-409) of the BREATHE-5 study (mean duration of treatment = 24.4  2.0 weeks) and, in general, efficacy was maintained.
Dvadeset i šest pacijenata nastavilo je primati bosentan tijekom 24-tjedne produžene faze liječenja (AC-052-409) ispitivanja BREATHE-5 (srednje trajanje liječenja = 24,4  2,0 tjedna), i općenito je djelotvornost bila održana.
Twenty-six patients continued to receive bosentan in the 24-week open-label extension phase (AC-052-409) of the BREATHE-5 study (mean duration of treatment = 24.4  2.0 weeks) and, in general, efficacy was maintained.
Dvadeset i šest pacijenata nastavilo je primati bosentan tijekom 24-tjedne produžene otvorene faze liječenja (AC-052-409) ispitivanja BREATHE-5 (srednje trajanje liječenja = 24,4  2,0 tjedna) i općenito je djelotvornost bila održana.
Twenty-two of 25 (88%) patients with haematologic complete remission also had minimal residual disease (MRD) responses (defined as MRD by PCR < 1 x 10-4).
Dvadeset i dva od 25 (88%) bolesnika s hematološki potpunom remisijom također je imalo odgovor na minimalnu rezidualnu bolest (MRB) (definiran kao MRB po PCR < 1 x 10-4).
Twice (2x)
dvaput (2x)
twice a day (approximately every 12 hours);
dva puta na dan (otprilike svakih 12 sati);
twice daily
2 puta dnevno
twice daily
2 x dnevno + OBT
twice daily
dnevno)
Twice daily
Dva puta na dan
Twice daily
Dvaput dnevno.
twice daily
puta dnevno
Twice Daily + 2 NRTI N=411
dvaput na dan
twice daily + OBT (N = 462)
400 mg dvaput
twice daily + OBT (N = 462)
Placebo +
twice daily by mouth with meals to lower your chance of an upset stomach.
dvaput na dan kroz usta s obrocima da smanjite mogućnost želučanih tegoba
Twice Daily Dose
Doziranje dva puta na dan 250 mg/m²
Twice Daily Dose
Doziranje dva puta na dan 300 mg/m²
Twice Daily Dose
Doziranje dva puta na dan 350 mg/m²
Twice daily dose 250 mg/m²
Doziranje dva puta na dan 250 mg/m²
Twice daily dose 300 mg/m²
Doziranje dva puta na dan 300 mg/m²
Twice daily dose 350 mg/m²
Doziranje dva puta na dan 350 mg/m²
Twice daily dosing
Doziranje dva puta na dan
Twice daily oral solution dose (dose in mg)
Doziranje oralne otopine dvaput na dan (doza u mg)
Twice daily oral solution dose (dose in mg/kg)
Doziranje oralne otopine dvaput na dan (doza u mg/kg)
twice daily regimen should be
600/100 mg dvaput na dan.
twice daily results in
dvaput na dan dovodi do povećanog rizika od
Twice daily treatment with 0.03% tacrolimus ointment was more effective than once daily administration (Table 3).
Liječenje dvaput na dan mašću s 0,03% takrolimusa bilo je djelotvornije nego primjena jedanput na dan (Tablica 3).
twice daily)
dvaput na dan)
twice daily/600 mg once daily)
dvaput na dan/600 mg jedanput na
Twice weekly (N=78)
Dvaput tjedno (N = 78)
Twice weekly Bortezomib Accord (cycles 1-4)
Bortezomib Accord dva puta tjedno (1.-4. ciklus)
Twice weekly Bortezomib Hospira (cycles 1-4)
Bortezomib Hospira dva puta tjedno (1.-4. ciklusa)
Twice weekly Bortezomib SUN (cycles 1-4)
Bortezomib SUN dva puta tjedno (1. – 4. ciklus)
twice weekly dosage of 150 mg
doze od 150 mg dvaput tjedno
twice weekly on set days is
150 mg dvaput tjedno u
twice-daily)
dvaput dnevno)
Twinrix Adult contains neomycin
Twinrix Adult sadrži neomicin
Twinrix Adult has no or negligible influence on the ability to drive and use machines.
Twinrix Adult ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Twinrix Adult is a combined vaccine formulated by pooling bulk preparations of the purified, inactivated hepatitis A (HA) virus and purified hepatitis B surface antigen (HBsAg), separately adsorbed onto aluminium hydroxide and aluminium phosphate.
Twinrix Adult je kombinirano cjepivo spravljeno puliranjem bulk pripravaka pročišćenog, inaktiviranog virusa hepatitisa A (HA) i pročišćenog površinskog antigena virusa hepatitisa B (HBsAg), odvojeno adsorbiranih na aluminijev hidroksid, odnosno aluminijev fosfat.
Twinrix Adult is a white, slightly milky liquid presented in a glass prefilled syringe (1 ml).
Twinrix Adult je bijela, lagano mliječna tekućina u napunjenoj staklenoj štrcaljki (1 ml).
Twinrix Adult is a white, slightly milky liquid presented in a glass vial (1 ml).
Twinrix Adult je bijela, lagano mliječna tekućina u staklenoj bočici (1 ml).
Twinrix Adult is available in packs of 1, 10, and 25.
Twinrix Adult je dostupan u pakiranjima od 1, 10 i 25.
Twinrix Adult is indicated for use in non immune adults and adolescents 16 years of age and above who are at risk of both hepatitis A and hepatitis B infection.
Twinrix Adult indiciran je za primjenu u neimunih odraslih osoba i adolescenata od navršene 16. godine života koji su pod rizikom od zaraze i hepatitisom A i hepatitisom B.
Twinrix Adult – Suspension for injection
Twinrix Adult – Suspenzija za injekciju
Twinrix Adult – Suspension for injection in prefilled syringe
Twinrix Adult – Suspenzija za injekciju u napunjenoj štrcaljki
Twinrix Adult, suspension for injection
Twinrix Adult, suspenzija za injekciju
Twinrix Adult, suspension for injection in prefilled syringe
Twinrix Adult, suspenzija za injekciju u napunjenoj štrcaljki
Twinrix Paediatric can be given with a Human Papillomavirus (HPV) vaccine at a separate injection site (another part of your body, e.g. the other arm) during the same visit.
Twinrix Paediatric može se dati istovremeno s cjepivom protiv humanog papilomavirusa (HPV) na odvojenim mjestima aplikacije (drugi dio tijela, npr. druga ruka) tijekom iste posjete liječniku.
Twinrix Paediatric contains neomycin
Twinrix Paediatric sadrži neomicin
Twinrix Paediatric is a combined vaccine formulated by pooling bulk preparations of the purified, inactivated hepatitis A (HA) virus and purified hepatitis B surface antigen (HBsAg), separately adsorbed onto aluminium hydroxide and aluminium phosphate.
Twinrix Paediatric je kombinirano cjepivo spravljeno puliranjem bulk pripravaka pročišćenog, inaktiviranog virusa hepatitisa A (HA) i pročišćenog površinskog antigena virusa hepatitisa B (HBsAg), odvojeno adsorbiranih na aluminijev hidroksid, odnosno aluminijev fosfat.
Twinrix Paediatric is a white, slightly milky liquid presented in a glass prefilled syringe (0.5 ml).
Twinrix Paediatric je bijela, lagano mliječna tekućina u napunjenoj staklenoj štrcaljki (0,5 ml).
Twinrix Paediatric is a white, slightly milky liquid presented in a glass vial (0.5 ml).
Twinrix Paediatric je bijela, lagano mliječna tekućina u staklenoj bočici (0,5 ml).
Twinrix Paediatric is available in packs of 1, 3 and 10.
Twinrix Paediatric je dostupan u pakiranjima od 1, 3 i 10.
Twinrix Paediatric is for intramuscular injection, preferably in the deltoid region in adolescents and children or in the anterolateral thigh in infants.
Twinrix Paediatric daje se intramuskularnom injekcijom, poželjno u deltoidno područje adolescentima i većoj djeci ili u anterolateralni dio bedra maloj djeci.
Twinrix Paediatric – Suspension for injection
Twinrix Paediatric – Suspenzija za injekciju
Twinrix Paediatric – Suspension for injection in prefilled syringe
Twinrix Paediatric – Suspenzija za injekciju u napunjenoj štrcaljki
Twinrix Paediatric, suspension for injection
Twinrix Paediatric, suspenzija za injekciju
Twinrix Paediatric, suspension for injection in prefilled syringe
Twinrix Paediatric, suspenzija za injekciju u napunjenoj štrcaljki
Twist + Pull Off
Zakrenite i odvojite
Twist and pull off Over-cap and Tip-cap.
Zakrenite i odvojite zatvarač i poklopac.
Twist clear cartridge slightly in the direction of the arrow to complete the “click” and center the number in the window.
Lagano zavrnite prozirni uložak u smjeru strelice kako biste čuli “klik” i centrirali broj u prozorčiću.
Twist knob to release injection button.
Okrenite kotačić da biste oslobodili gumb za injiciranje.
Twist off administration syringe from vial adapter.
Zakretanjem odvojite štrcaljku za primjenu lijeka od nastavka za bočicu.
Twist off the bottle cap.
Odvrnite zatvarač boce.
Twist off the bottle cap.
Odvrnite zatvarač bočice.
Twist off the bottle cap.
Odvrnite čep bočice.
Twist off the cap
Odvrnite zatvarač
Twist off the cap
Otvorite poklopac
Twist off the cap (picture 1).
Odvijte čep (slika 1).
Twist off the cap in the direction of the arrows.
Poklopac skinite okretom u smjeru strelica.
Twist off the cap.
Otvorite poklopac.
twist or bend the grey needle cap.
okretati ili savijati sivi zatvarač igle.
Twist pen to mix your medicine
Zavrnite brizgalicu da biste pomiješali lijek
Twist pen to prime the needle
Zavrnite brizgalicu kako biste provjerili protok lijeka.
Twist the safety needle firmly onto the syringe as far as it will go.
Čvrsto zavrnite sigurnosnu iglu na štrcaljku sve do kraja.
Twist the top of the case in a clockwise direction until it is closed tighly.
Zavijte vrh spremnika u smjeru kazaljke na satu dok ne bude čvrsto zatvoren.
twist, bend or wiggle the orange cap.
okretati ili savijati narančasti zatvarač.
Twist-off base cap
Zatvarač baze koji se može odvrnuti i
Twisting of an ovary (ovarian torsion)
uvrtanje jajnika (torzija jajnika)
Twitching (B)
trzanje mišića (B)
Two (2) patients underwent reportedly the rapid elimination procedure; however, the outcome was unknown for both patients.
Dva (2) su bolesnika, prema prijavi, bila podvrgnuta postupku ubrzane eliminacije, međutim, ishod je za oba bolesnika nepoznat.
Two (2) patients were excluded from the per-protocol analysis because their WBC cystine level increased over 2 nmol hemicystine/mg protein during the immediate-release cysteamine treatment period.
Dva (2) ispitanika su isključena iz analize prema planu ispitivanja jer se njihova razina cistina u leukocitima povećala iznad 2 nmola hemicistina/mg proteina tijekom razdoblja liječenja cisteaminom s trenutačnim oslobađanjem.
Two (2/957, 0.2%) of these tolvaptan treated-patients, as well as a third patient from an extension open label trial, exhibited increases in hepatic enzymes (>3xULN) with concomitant elevations in BT (>2xULN).
Od tih bolesnika liječenih tolvaptanom u njih dvojice (2/957; 0,2%), kao i u još jednog, trećeg, bolesnika iz produžetka otvorenog ispitivanja, došlo je do porasta jetrenih enzima (>3 x GGN) uz istovremen porast ukupnog bilirubina (>2 x GGN).
Two 10 mg capsules
Dvije kapsule od 10 mg
Two 10 mg capsules plus one 4 mg capsule
Dvije kapsule od 10 mg plus jedna kapsula od 4 mg
Two 10 mg tablets once a day
dvije tablete od 10 mg jedanput na dan
two 10 mg tablets once a day
dvije tablete od 10 mg jednom dnevno
two 10 mg tablets or one 20 mg tablet once a day
dvije tablete od 10 mg ili jedna tableta od 20 mg jedanput na dan
Two 19-gauge, 50 mm Hypodermic safety needles
Dvije hipodermalne zaštićene igle od 19G i duljine 50 mm
Two 20-mg vials reconstituted with 1.2 mL solvent each
Dvije bočice od 20 mg svaka rekonstituirana s 1,2 ml otapala
two 200 mg capsules
dvije kapsule od 200 mg
Two 320 mg/40 mg tablets a day
Dvije tablete od 320 mg/40 mg na dan
Two 4 mg capsules
Dvije kapsule od 4 mg
Two 5 mg tablets
dvije tablete od 5 mg
Two additional studies looked at the effects of Tracleer dispersible tablets in children: the first study included 36 children with PAH who were aged between two and 11 years, while the second study included 64 children with PAH from three months up to 11 years of age.
Dva dodatna ispitivanja istražila su djelovanje disperzibilnih tableta lijeka Tracleer u djece: prvo ispitivanje obuhvatilo je 36-ero djece s PAH-om u dobi između dvije i 11 godina starosti, dok je drugo ispitivanje obuhvatilo 64-ero djece s PAH-om u dobi između tri mjeseca i 11 godina starosti.
Two alcohol pads (4)
Dva alkoholom natopljena jastučića (4)
two alcohol swabs
dvije alkoholom natopljene vatice
two alcohol swabs
dvije vatice natopljene alkoholom
two alcohol swabs for single use
dva tupfera natopljena alkoholom za jednokratnu primjenu
two alcohol swabs,
dvije blazinice natopljene alkoholom,
two alcohol swabs, one pre-filled syringe containing the medicinal product
dvije blazinice natopljene alkoholom, jednu napunjenu štrcaljku koja sadrži lijek.
two alcohol swabs, one syringe of Zutectra, one needle suitable for subcutaneous injection.
dvije gaze natopljene alkoholom, jednu štrcaljku lijeka Zutectra, jednu iglu prikladnu za potkožnu injekciju.
Two children on fluticasone propionate/salmeterol and 5 children on fluticasone propionate withdrew because of worsening asthma.
Dvoje djece koje je primalo flutikazonpropionat/salmeterol i 5 djece koja su primala flutikazonpropionat povuklo se iz ispitivanja zbog pogoršanja astme.
Two clinical studies evaluated the immunogenicity of Pandemrix in healthy subjects aged 18-60 years.
Imunogenost cjepiva Pandemrix procjenjivala se u dva klinička ispitivanja na ispitanicima u dobi od 18-60 godina.
Two clinically silent, low-titre, transient inhibitors were observed in 94 patients with a median exposure of 76 exposure days (ED, range 1-92), corresponding to 2.2% of the 89 patients with at least 50 ED.
Dva klinički tiha, prolazna inhibitora s niskim titrom bila su opažena u 94 bolesnika s medijanom izloženosti od 76 dana izloženosti (ED, raspon 1- 92), što odgovara 2,2% od 89 bolesnika koji su imali barem 50 ED.